Spinal cord injury (SCI) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Indication name: Spinal cord injury (SCI)

Spinal cord injury (SCI) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

A spinal cord injury (SCI) is damage to the spinal cord that results in a loss of function, such as mobility and/or feeling. Spinal cord injuries are most often the result of vehicle accidents, which account for 39.3% of SCI cases, followed closely by falls (31.8%). Other causes include acts of violence (primarily gunshot wounds) at 13.5% and sports-related injuries at 8%.

Spinal cord injury can be classified into four categories: cervical, thoracic, lumbar and sacral.

Cervical spinal cord injuries usually cause loss of function in the arms and legs, resulting in quadriplegia

The 12 vertebra in the chest are called the thoracic vertebra.

The vertebra in the lower back between the thoracic vertebra, where the ribs attach, and the pelvis (hip bone), are the lumbar vertebra.

The sacral vertebra run from the pelvis to the end of the spinal column.

SCIs are graded according to the American Spinal Injury Association (ASIA) grading scale, which describes the severity of the injury. The scale is graded with letters:

ASIA A: injury is complete spinal cord injury with no sensory or motor function preserved.

ASIA B: a sensory incomplete injury with complete motor function loss.

ASIA C: a motor incomplete injury, where there is some movement, but less than half the muscle groups are anti-gravity (can lift up against the force of gravity with a full range of motion).

ASIA D: a motor incomplete injury with more than half of the muscle groups are anti-gravity.

ASIA E: normal.

Epidemiology- According to Thelansis, an estimated 311,000 people in the United States are living with spinal cord injuries (SCIs). There are approximately 19,350 new SCIs every year, most of which are caused by automobile accidents and falls. About ~80% of new SCI cases are male.

 

Competitive landscape of Spinal cord injury (SCI) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Spinal cord injury (SCI) across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. KOL Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Spinal cord injury (SCI) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Spinal cord injury (SCI) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No        Asset        Company        Stage

1        FAB117-HC        Ferrer Internacional S.A.        Phase 2

2        AXER-204        ReNetX Bio, Inc.        Phase 2

3        KP-100IT        Kringle Pharma, Inc.        Phase 3

4        SC0806 and rehabilitation        BioArctic AB        Phase 2

5        Cethrin        Vertex Pharmaceuticals Incorporated        Phase 2

6        Neuro-Cells        Neuroplast        Phase 1

7        ES135        Eusol Biotech Co., Ltd.        Phase 3

8        GRNOPC1        Lineage Cell Therapeutics, Inc.        Phase 1

9        MT-3921        Mitsubishi Tanabe Pharma Development America, Inc.        Phase 2

10        Elezanumab        AbbVie        Phase 2